The BrIDGs program assists researchers in advancing promising therapeutic agents through late-stage pre-clinical development toward an Investigational New Drug (IND) application and clinical testing. Learn more.
An analysis finds that two NCATS rare diseases programs have led to reduced costs for developing new drugs and reduced financial risks.
Work with Us
The 2015 project solicitation is coming soon! Check back this spring for more information about applying to work with the BrIDGs program.
Bridging Interventional Development Gaps (BrIDGs)
Find out more about the BrIDGs program and its role in advancing new therapeutics.
BrIDGs offers state-of-the-art expertise and resources for pre-clinical development.
Work with BrIDGs
Learn how to collaborate with the BrIDGs program and access crucial resources.
Why BrIDGs Matters
As of fall 2014, BrIDGs has generated data to support 15 INDs that have been cleared by the FDA and one clinical trial application cleared by Health Canada. A total of 14 projects have been evaluated in clinical trials. Five BrIDGs-supported agents have gone as far as phase II human clinical trials, in which researchers give an experimental therapy to a group of patients to evaluate the effectiveness and safety of a treatment. Third-party investors have licensed seven agents during or after their development by BrIDGs. Learn more about BrIDGs projects.